Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p ≤ 0.002) Patients in the RADIANT study of vormatrigine showed rapid, consistent and durable improvement in seizure reduction, reaching 100% for patients continuing through 16 weeks Expansion of the Praxis Analysis of Concordance Framework to include DEEs Showcase of the most compr ...